WallStSmart

Abbott Laboratories (ABT)vsReWalk Robotics Ltd (LFWD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 213377% more annual revenue ($46.59B vs $21.82M). ABT leads profitability with a 11.7% profit margin vs -141.3%. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LFWD

Avoid

34

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -18.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$101.95

$27.82 premium

UndervaluedFair: $74.13Overvalued

Intrinsic value data unavailable for LFWD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

LFWD2 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.7%8/10

15.7% revenue growth

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

LFWD4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.11M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-209.1%2/10

ROE of -209.1% — below average capital efficiency

Free Cash FlowQuality
$-6.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : LFWD

The strongest argument for LFWD centers on Price/Book, Revenue Growth. Revenue growth of 15.7% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : LFWD

The primary concerns for LFWD are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while LFWD is a growth play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.59 — expect wider price swings.

LFWD is growing revenue faster at 15.7% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (54/100 vs 34/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

ReWalk Robotics Ltd

HEALTHCARE · MEDICAL DEVICES · USA

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company is headquartered in Yokneam Illit, Israel.

Want to dig deeper into these stocks?